247254-47-3

Basic information

• Product Name: 3-BROMO-4-METHOXYBENZYLAMINE
• Synonyms: 3-BROMO-4-METHOXYBENZYLAMINE;RARECHEM AL BW 0769;[[3-Bromo-4-(methyloxy)phenyl]methyl]amine;3-Bromo-4-methoxy-benzenemethanamine;(3-bromo-4-methoxyphenyl)methanamine
• CAS NO: 247254-47-3
• Molecular Formula: C₈H₁₀BrNO
• Molecular Weight: 216.08
• Product Categories: Anilines, Aromatic Amines and Nitro Compounds
• Mol File: 247254-47-3.mol

Chemical Properties

• Boiling Point: 290.249°C at 760 mmHg
• Flash Point: 129.338°C
• Appearance: /
• Density: 1.444g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-BROMO-4-METHOXYBENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-METHOXYBENZYLAMINE(247254-47-3)
• EPA Substance Registry System: 3-BROMO-4-METHOXYBENZYLAMINE(247254-47-3)

Safety Data

• Hazardous Substances Data: 247254-47-3(Hazardous Substances Data)

Usage

Uses

Used in Chemical Industry:
3-Bromo-4-methoxybenzylamine is used as a chemical intermediate for the synthesis of various compounds. Its unique structure with a bromine atom and methoxy group allows for versatile reactions and transformations, making it a valuable component in the production of specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 3-Bromo-4-methoxybenzylamine serves as a key intermediate in the synthesis of drugs. Its presence in the molecular structure can contribute to the development of new therapeutic agents, potentially leading to advancements in medicine and healthcare.
Used in Research and Development:
3-Bromo-4-methoxybenzylamine is also utilized in research and development settings, where it can be employed to study the effects of different substituents on the chemical properties and reactivity of benzylamines. This knowledge can be instrumental in designing new molecules with specific characteristics and applications.

InChI:InChI=1/C8H10BrNO/c1-11-8-3-2-6(5-10)4-7(8)9/h2-4H,5,10H2,1H3

Upstream product

• 117572-79-9 3-bromo-4-methoxybenzonitrile 

Downstream Products

• 1177558-30-3 N-{[3-bromo-4-(methyloxy)phenyl]methyl}-N'-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-5-methyl-1,3-benzenedicarboxamide 
• 1177558-79-0 N-{[3-Bromo-4-(methyloxy)phenyl]methyl}-N'-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-1,3-benzenedicarboxamide 
• 1181078-32-9 E N-{[3-Bromo-4-(methyloxy)phenyl]methyl}-N'-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}propanediamide 
• 1181078-40-9 N-{[3-bromo-4-(methyloxy)phenyl]methyl}-N'-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}butanediamide 

Relevant articles and documents

Discovery of EBI-907: A highly potent and orally active B-RafV600Einhibitor for the treatment of melanoma and associated cancers

A novel series of pyrazolo[3,4-c]isoquinoline derivatives was discovered as B-RafV600Einhibitors through scaffold hopping based on a literature lead PLX4720. Further SAR exploration and optimization led to the discovery of potent B-RafV600

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.